Theravance Biopharma (NASDAQ:TBPH) Given Buy Rating at BTIG Research

BTIG Research restated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note issued to investors on Friday morning,Benzinga reports. BTIG Research currently has a $21.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the company. Wall Street Zen cut Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. B. Riley Financial reiterated a “neutral” rating and issued a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. HC Wainwright lifted their target price on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Theravance Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $22.60.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $14.33 on Friday. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03. The firm has a market capitalization of $726.10 million, a P/E ratio of 7.06 and a beta of 0.17. The company’s 50-day moving average is $18.00 and its 200 day moving average is $16.85.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Wednesday, March 25th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.71. The business had revenue of $45.89 million during the quarter, compared to analyst estimates of $43.09 million. Theravance Biopharma had a return on equity of 18.55% and a net margin of 98.54%. Research analysts anticipate that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. This represents a 11.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TBPH. Vanguard Group Inc. increased its holdings in shares of Theravance Biopharma by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after purchasing an additional 54,152 shares during the last quarter. State Street Corp boosted its stake in Theravance Biopharma by 4.4% during the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock worth $20,616,000 after buying an additional 45,987 shares during the last quarter. Geode Capital Management LLC boosted its stake in Theravance Biopharma by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock worth $17,567,000 after buying an additional 40,734 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Theravance Biopharma by 12.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after buying an additional 92,253 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Theravance Biopharma in the 3rd quarter worth $10,611,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

More Theravance Biopharma News

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company highlights and cash/milestone strength — Theravance reported record brand-level profitability for YUPELRI®, received milestone payments tied to sales, expects ~ $400M in cash at end-Q1 2026 with no debt, and announced cost-reduction targets to generate $60–$70M of annualized cash flow starting Q3 2026. Theravance Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Analyst optimism — BTIG reaffirmed a buy rating and set a $21 price target (material upside from current levels), and Zacks upgraded TBPH to a Rank #1 (Strong Buy), supporting the short-term positive sentiment. Benzinga Zacks: Rating Upgrade to Strong Buy
• Neutral Sentiment: Mixed earnings coverage — company releases show strong non‑GAAP profitability and reported milestone-driven revenue, but media/analytics outlets are publishing differing EPS figures (reports vary between a beat and a miss depending on metric/adjustment). Investors should check the company filing for GAAP vs. non‑GAAP reconciliations. Press Release — Q4 and Full Year 2025 Results Zacks: Q4 Earnings and Revenues Lag Estimates
• Negative Sentiment: Pipeline setback and strategic review — management discontinued ampreloxetine after Phase 3 CYPRESS results, is implementing a restructuring, and has formed a Strategic Review Committee to evaluate options including a potential sale — these actions reduce near-term R&D upside and signal material change in corporate strategy. Zacks: Q4 Earnings and Revenues Miss; Ampreloxetine Scrapped
• Negative Sentiment: Insider selling — SVP Rhonda Farnum sold ~31,067 shares in mid‑March; while not definitive, the sale is being watched by investors as a near-term negative signal. InsiderTrades: SVP Sells Shares

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.